Astonea Labs Ltd (ASTONEALAB) — shareholding pattern, promoter holding, financials and share price
About Astonea Labs Ltd (ASTONEALAB)
Astonea Labs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ASTONEALAB and on the BSE under scrip code 544409. Its ISIN is INE0TG901011.
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies [1]
Astonea Labs Ltd is focused on manufacturing and marketing pharmaceutical and cosmetic products, including antibiotics and multivitamins, used for skin, hair, and tooth care.
The company also operates as a contract manufacturer for both domestic and international firms, highlighting its expansive operational reach.
Listed peers in Pharmaceuticals: Medico Remedies Ltd, Infinium Pharmachem Ltd, Trident Lifeline Ltd, Everest Organics Ltd, BDH Industries Ltd, Zenotech Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹282.55 a share on 10 Jul 2026, Astonea Labs Ltd (ASTONEALAB) was valued at a price-to-earnings ratio of 65.71x against an industry P/E of 36.41x and a price-to-book of 5.2x on a book value of ₹54.35 per share. Solomo computes return on equity of 7.9% and return on capital employed of 8.87% from filed results.
- P/E
- 65.71x
- Industry P/E
- 36.41x
- P/B
- 5.2x
- EPS (TTM)
- ₹4.3
- Book value / share
- ₹54.35
- ROE
- 7.9%
- ROCE
- 8.87%
- ROA
- 3.09%
- Debt / equity
- 0.75x
- Dividend yield
- 0%
- EBITDA margin
- 9.41%
- 52-week range
- ₹118 – ₹301.3
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Astonea Labs Ltd (ASTONEALAB) reported revenue of ₹148 crore, net profit of ₹5 crore and earnings per share of ₹4.3. That compares with revenue of ₹97 crore and net profit of ₹5 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹81 crore and net profit ₹3 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 30 | 67 | 80 | 97 | 148 |
| Net profit (₹ cr) | 0 | 1 | 4 | 5 | 5 |
| EPS (₹) | 0.62 | 1.68 | 5.36 | 6.93 | 4.3 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 48.04% | 21.61% |
| Profit growth | 178.09% | 31.45% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 72.3% of Astonea Labs Ltd (ASTONEALAB), foreign institutional investors (FII) hold 0% and domestic institutional investors (DII) hold 0.07%. Market capitalisation was ₹297 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2025.
Largest disclosed public shareholders in Mar 2026: GURVINDER SINGH BHULLAR 2.87%, SWATI AGARWALA 2.62%, DEEPAK KUMAR AGARWAL 2.15%, MRIDUL AGARWAL 1.46%, PADMAWATI REALCON PRIVATE LIMITED 1.11%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 72.3% | - | 0% | 0.07% | 27.7% |
| Sep 2025 | 72.3% | - | 2.51% | 0.35% | 27.7% |